WallStSmart
SXTP

60 Degrees Pharmaceuticals, Inc. Common Stock

NASDAQ: SXTP · HEALTHCARE · BIOTECHNOLOGY

$1.50
-7.19% today

Updated 2026-06-05

Market cap
$3.67M
P/E ratio
P/S ratio
2.79x
EPS (TTM)
$-6.76
Dividend yield
52W range
$1 – $11
Volume
0.1M

60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item202020212022202320242025
Total assets$2.61M$1.39M$1.30M$7.78M$5.76M$5.37M
Cash & equivalents$191702.00$115399.00$264865.00$2.14M$1.66M$1.51M
Current assets$2.44M$1.18M$1.10M$7.24M$5.39M$4.90M
Total liabilities$20.68M$19.55M$25.45M$2.99M$1.80M$1.99M
Current liabilities$1.43M$635473.00$23.92M$2.84M$1.66M$1.84M
Long-term debt$15.92M$18.74M$1.27M$150251.00$147119.00$144003.00
Shareholder equity$-17.50M$-17.58M$-23.58M$4.87M$4.04M$3.46M
Retained earnings$-18.38M$-22.63M$-28.82M$-32.58M$-40.53M$-47.89M
Accounts receivable$859425.00$146362.00$45965.00$231332.00$486748.00$509644.00
Inventory$1.04M$689042.00$518578.00$466169.00$442764.00$656924.00
Goodwill

Frequently asked questions

What is 60 Degrees Pharmaceuticals, Inc. Common Stock's revenue?

60 Degrees Pharmaceuticals, Inc. Common Stock's trailing twelve-month revenue is $1.31M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is SXTP?

In its most recent fiscal year, SXTP ran a gross margin of 22.26%, an operating margin of -771.64%, and a net margin of -732.82%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does SXTP generate?

SXTP produced $-7.07M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is SXTP's balance sheet healthy?

SXTP holds $1.51M in cash and equivalents against $144003.00 in long-term debt, on $3.46M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.